The vector of anti-LMP2 T cell receptor (TCR) is constructed for the engineering of T cell to target EBV LMP2. The T cells are genetically modified through transduction with a retroviral vector expressing LMP2-specific T cell receptor. And the vector product was designed for the treatment of Hodgkin's Disease and Nasopharyngeal Carcinoma.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|VP-TCR-C210||Lenti-LMP2 T cell receptor (PL5.04) Viral Particle|
|VP-TCR-C208||Lenti-LMP2 T cell receptor (NB20) Viral Particle|
|VP-TCR-C215||Lenti-EBV (TYPVLEEMF) T cell receptor Viral Particle|
|TCR-L016||Human anti-LMP2 (AVFDRKSDAK) T Cell Receptor, pMP71|
|VP-TCR-C209||Lenti-LMP2 T cell receptor (PL5.05) Viral Particle|
|VP-TCR-C213||Lenti-EBV T cell receptor (Cysteine-modiﬁed) Viral Particle|
|VP-TCR-C211||Lenti-LMP2 Murinized T cell receptor Viral Particle|
|TCR-L018||Human anti-LMP2 (TYPVLEEMF) T Cell Receptor, pMX-IRES-GFP|
|TCR-C111Z||Human anti-LMP2 T cell receptor (PL5.04), pCDTCR1|
|TCR-L056||Human anti-LMP2 (CLGGLLWT) T Cell Receptor, pSFG|
Copyright © 2007 - 2018 Creative Biolabs. All Rights Reserved